Adcoris is a clinical stage biopharmaceutical company focusing on developing the next generation antibody drug conjugate (ADC) and antibody conjugate beyond cytotoxic payload (AXC) therapeutics to address the unmet needs in oncology and autoimmune disease. Our state-of-the-art proprietary technology platform is based on internally developed three pillars of ADC technologies: proprietary and highly active payloads (PHAP™); cleavable, flexible and stable linkers (CLEF™), multifunctional site-specific conjugation (MuSC™). We can accelerate the development of ADC and AXC from target to IND enabling within 15 months. We have built a robust product pipeline including first-in-class (FIC) and first-in-generation (FIG) ADC and AXC in various development stages. One ADC product has finished phase 1 clinical study with excellent safety and efficacy profiles. 3 FIC and 4 FIG products are in IND-enabling and preclinical candidate stage.

Adcoris was started by a group of highly experienced experts with rich experience in ADC, medicinal chemistry, biotechnology, pharmacology, management and business development. Adcoris is well positioned to play a leading role in the era of new generation antibody bioconjugate therapeutics, i.e., ADC and AXC.

For more information，please contact us at BD@adcoris.com.cn.